![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Gilead Sciences Partners with Gritstone Oncology for HIV Cure
Gilead Sciences Partners with Gritstone Oncology for HIV Cure
![Partner Up, blocks](https://www.fdanews.com/ext/resources/test/Drug-Images4/Partner-Up-blocks.gif?t=1593635821&width=430)
February 3, 2021
Gilead Sciences and Gritstone Oncology have teamed up to develop a vaccine-based immunotherapy to cure HIV infection.
Under the agreement, the companies will leverage Gritstone’s vaccine platform, which uses both messenger-RNA and adenovirus-based vectors, as well as antigens produced by Gilead, which will be spearheading a phase 1 study of the HIV therapeutic vaccine candidate.
Gritstone will receive $60 million upfront and is eligible to receive up to $725 million based on reaching certain development and sales-based milestones and future royalties.
Upcoming Events
-
21Oct